Literature DB >> 3970690

Structural identification of platelet activating factor in psoriatic scale.

A I Mallet, F M Cunningham.   

Abstract

Platelet activating factor was isolated from the lesional scale of psoriatic patients using the method described by Bligh and Dyer (8). The extract was subjected to thin layer chromatography, and the region of the plate co-migrating with platelet activating factor removed. A portion of each sample was assayed for aggregating activity using washed guinea-pig platelets and the remainder treated with phospholipase C, derivatised, and subjected to reversed phase high performance liquid chromatography. Fractions were analysed for platelet activating factor using capillary gas chromatography-mass spectrometry. Nanogram quantities of platelet activating factor were recovered from 100 mg scale and both the C16 and C18 alkyl substituents were present in the ratio 3:1, C16:C18.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970690     DOI: 10.1016/0006-291x(85)90590-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Platelet-activating factor induces proliferation in differentiated keratinocytes.

Authors:  Astrid J Feuerherm; Katarina M Jørgensen; Randi M Sommerfelt; Live E Eidem; Astrid Lægreid; Berit Johansen
Journal:  Mol Cell Biochem       Date:  2013-08-24       Impact factor: 3.396

3.  Effect of locally applied WEB 2086, a platelet-activating factor antagonist, on inflammatory skin conditions in mice.

Authors:  L Kemény; V Trach; A Dobozy
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

4.  Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man.

Authors:  J Arnout; A van Hecken; I De Lepeleire; Y Miyamoto; I Holmes; P De Schepper; J Vermylen
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

5.  Psoriatic skin lesions contain a novel lipid neutrophil chemokinetic compound which is distinct from known chemoattractant eicosanoids.

Authors:  R D Camp; F M Cunningham; N J Fincham; M W Greaves; A Kobza Black; A I Mallet; P M Woollard
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

6.  Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment.

Authors:  R M Barr; F Lawlor; M R Judge; P Courtney; R Barlow; A Kobza Black; A I Mallet; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

7.  Interleukin-8 stimulates the formation of 15-hydroxy-eicosatetraenoic acid by human neutrophils in vitro.

Authors:  K Fogh; C G Larsen; L Iversen; K Kragballe
Journal:  Agents Actions       Date:  1992-03

Review 8.  Leukotriene B4 and platelet-activating factor in human skin.

Authors:  L Michel; L Dubertret
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

9.  Identification and quantitation of PAF from psoriatic scales.

Authors:  C S Ramesha; N Soter; W C Pickett
Journal:  Agents Actions       Date:  1987-08

10.  Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation.

Authors:  D Tsoukatos; C A Demopoulos; A D Tselepis; M C Moschidis; A Donos; A Evangelou; J Benveniste
Journal:  Lipids       Date:  1993-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.